Novavax NVAX Royalties — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Novavax’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001000694-26-000018
The Company is eligible to receive milestone payments totaling up to $350 million in the aggregate with respect to the COVID-19 Vaccine products, of which $75 million due upon completion of the technology transfer of the Company’s manufacturing process for the COVID-19 Vaccine products to Sanofi remains outstanding, and royalty payments in the high teens to low twenties percent on Sanofi’s sales of such licensed products. During the three and six month period ended June 30, 2026, the Company recognized $0.7 million and $4.2 million of royalties on Sanofi sales of COVID-19 Vaccine products, respectively.
Item 1. Consolidated Financial Statements
FAQ
- What is Novavax's royalties — total revenue?
- Novavax (NVAX) reported royalties — total revenue of $700K in Q2 2026.
- How has Novavax's royalties — total revenue changed year-over-year?
- Novavax's royalties — total revenue decreased by 86.0% year-over-year, from $5M to $700K.
- What does royalties — total revenue mean?
- This metric represents the total gross revenue generated from licensing intellectual property, patents, or proprietary vaccine technology to third-party partners. It reflects the company's ability to monetize its research and development pipeline through passive income streams rather than direct product sales. Growth in this segment indicates successful commercial adoption of the company's technology by external entities.
Ask your AI about Novavax's royalties — total revenue.
Connect your AI assistant and compare segments, right in your chat.
